DNA cross-linking patterns induced by an antitumor-active trinuclear platinum complex and comparison with its dinuclear analogue.

The DNA binding and cross-linking modes of a trinuclear platinum complex [Pt(3)Cl(3)(hptab)][ClO(4)](3) (1; hptab = N,N,N',N',N'',N''-hexakis(2-pyridylmethyl)-1,3,5-tris(aminomethyl)benzene) and its dinuclear analogue [Pt(2)Cl(2)(m-tpxa)]Cl(2) (2; m-tpxa = N,N,N',N'-tetra(2-pyridylmethyl)-m-xylylene diamine) are reported and compared. The adducts of 1 and 2 with 18-mer duplex N1, 5'-d(GAAGAAGTCACAAAATGT)-3'5'-d(ACATTTTGTGACTTCTTC)-3', have been characterized by means of denaturing polyacrylamide gels, Maxam-Gilbert sequencing, and MALDI-TOF mass spectrometry combined with enzymatic degradation to obtain insights into structural features responsible for the differences in their antitumor activities. The cytotoxic-active complex 1 readily forms various DNA adducts, such as through 1,3- and 1,4-intrastrand cross-links, and in particular, the unique and unprecedented interstrand cross-linked triadducts. In contrast, the cytotoxic-inactive complex 2 preferentially forms 1,4-intrastrand rather than 1,3-intra- and -interstrand cross-links. Digestion of the DNA adducts of 1 shows that the cleavage is completely blocked at one nucleotide before the cross-linked guanine residues on the opposite strand, a feature that appears to be unprecedented in antitumor platinum complexes. In the case of 2, the cleavage bypasses the first platinated guanine site and stops at one nucleotide prior to the second platinated site, confirming that very few 1,3-intrastrand cross-links are formed by 2. These results are supported by molecular-modeling studies of intra- and interstrand cross-links of duplex N1 with 1 and 2. The remarkable differences between 1 and 2 in DNA binding and cross-linking provide mechanistic insights into their different cytotoxicity against the tumor cell lines; these insights are useful for designing future antitumor agents.

[1]  Zijian Guo,et al.  Towards the rational design of platinum(II) and gold(III) complexes as antitumour agents. , 2008, Dalton transactions.

[2]  Stephen J Lippard,et al.  Direct cellular responses to platinum-induced DNA damage. , 2007, Chemical reviews.

[3]  Jian Ding,et al.  A dinuclear monofunctional platinum(II) complex with an aromatic linker shows low reactivity towards glutathione but high DNA binding ability and antitumor activity , 2007, JBIC Journal of Biological Inorganic Chemistry.

[4]  E. Pedroso,et al.  Selective platination of modified oligonucleotides and duplex cross-links. , 2006, Angewandte Chemie.

[5]  Lin Qiu,et al.  A positively charged trinuclear 3N-chelated monofunctional platinum complex with high DNA affinity and potent cytotoxicity. , 2006, Dalton transactions.

[6]  Mika Kettunen,et al.  Platinum group antitumor chemistry: design and development of new anticancer drugs complementary to cisplatin. , 2006, Current medicinal chemistry.

[7]  N. Farrell,et al.  A surprisingly stable macrochelate formed from the reaction of cis dinuclear platinum antitumor compounds with reduced glutathione. , 2005, Inorganic chemistry.

[8]  E. Pedroso,et al.  Insights into the reaction of transplatin with DNA and proteins: methionine-mediated formation of histidine-guanine trans-Pt(NH3)2 cross-links. , 2004, Chemistry.

[9]  N. Farrell,et al.  Long range 1,4 and 1,6-interstrand cross-links formed by a trinuclear platinum complex. Minor groove preassociation affects kinetics and mechanism of cross-link formation as well as adduct structure. , 2004, Journal of the American Chemical Society.

[10]  Zijian Guo,et al.  Toward the design of novel polynuclear platinum antitumor complexes: a polydentate ligand system based on dipyridylamine and 1,3,5-trimethylenebenzene. , 2003, Inorganic chemistry.

[11]  N. Farrell,et al.  Reaction of polynuclear platinum antitumor compounds with reduced glutathione studied by multinuclear (1H, 1H-15N gradient heteronuclear single-quantum coherence, and 195Pt) NMR spectroscopy. , 2003, Inorganic chemistry.

[12]  S. Bombard,et al.  Kinetic study of azole-bridged dinuclear platinum(II) complexes reacting with a hairpin-stabilized double-stranded oligonucleotide. , 2003, Journal of inorganic biochemistry.

[13]  R. Lobinski,et al.  Sensitive species-specific monitoring of a new triplatinum anti-cancer drug and its potential related compounds in spiked human plasma by cation-exchange HPLC-ICP-MS , 2003 .

[14]  Chunhua Yan,et al.  Monofunctional platinum complexes showing potent cytotoxicity against human liver carcinoma cell line BEL-7402. , 2003, Journal of medicinal chemistry.

[15]  J. Collins,et al.  Multi-nuclear platinum complexes as anti-cancer drugs , 2003 .

[16]  Jan Reedijk,et al.  New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  S. Bombard,et al.  Platinum cross-linking of adenines and guanines on the quadruplex structures of the AG3(T2AG3)3 and (T2AG3)4 human telomere sequences in Na+ and K+ solutions. , 2003, Nucleic acids research.

[18]  N. Farrell,et al.  Competitive reactions of interstrand and intrastrand DNA-Pt adducts: A dinuclear-platinum complex preferentially forms a 1,4-interstrand cross-link rather than a 1,2 intrastrand cross-link on binding to a GG 14-mer duplex. , 2003, Chemistry.

[19]  J. Perez,et al.  Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. , 2003, Current medicinal chemistry.

[20]  G. A. van der Marel,et al.  Monofunctionally trans-diammine platinum(II)-modified peptide nucleic acid oligomers: a new generation of potential antisense drugs. , 2002, Chemistry.

[21]  V. Brabec,et al.  DNA Interstrand Cross-links of the Novel Antitumor Trinuclear Platinum Complex BBR3464 , 2002, The Journal of Biological Chemistry.

[22]  V. Brabec,et al.  Molecular aspects of resistance to antitumor platinum drugs. , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[23]  P. Sharp,et al.  Transcription-coupled and DNA damage-dependent ubiquitination of RNA polymerase II in vitro , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  V. Brabec.  DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. , 2002, Progress in nucleic acid research and molecular biology.

[25]  T. Uchimaru,et al.  Dinucleotide Hydrolysis Promoted by Dinuclear Zn Complexes − The Effect of the Distance between Zn Ions in the Complexes on the Hydrolysis Rate , 2001 .

[26]  A. Ogdie,et al.  Locating nucleobase lesions within DNA sequences by MALDI-TOF mass spectral analysis of exonuclease ladders. , 2001, Chemical research in toxicology.

[27]  J. Essigmann,et al.  Recognition of cisplatin adducts by cellular proteins. , 2001, Mutation research.

[28]  Trevor W. Hambley,et al.  Molecular mechanics modelling of Pt/nucleotide and Pt/DNA interactions , 2001 .

[29]  P. Sadler,et al.  Sequence-dependent bending of DNA induced by cisplatin: NMR structures of an A.T-rich 14-mer duplex. , 2000, Chemistry.

[30]  S. Lippard,et al.  Structure, Recognition, and Processing of Cisplatin-DNA Adducts. , 1999, Chemical reviews.

[31]  W. Shepard,et al.  Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 A resolution: hydration at the platinated site. , 1999, Nucleic acids research.

[32]  S. Lippard,et al.  NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin. , 1998, Biochemistry.

[33]  S. Lippard,et al.  Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin , 1995, Nature.

[34]  John A. Tainer,et al.  Structure and function of the multifunctional DNA-repair enzyme exonuclease III , 1995, Nature.

[35]  F. Collins,et al.  Somatic mutations in the BRCA1 gene in sporadic ovarian tumours , 1995, Nature Genetics.

[36]  Luigi G. Marzilli,et al.  A Molecular Mechanics AMBER-Type Force Field for Modeling Platinum Complexes of Guanine Derivatives , 1994 .

[37]  P. Kollman,et al.  A well-behaved electrostatic potential-based method using charge restraints for deriving atomic char , 1993 .

[38]  V. Brabec,et al.  DNA interstrand cross-links of trans-diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[39]  S. Lippard,et al.  Unwinding of supercoiled DNA by platinum-ethidium and related complexes , 1992 .

[40]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[41]  R. Lavery,et al.  Defining the structure of irregular nucleic acids: conventions and principles. , 1989, Journal of biomolecular structure & dynamics.

[42]  W. Linxweiler,et al.  Sequence specificity of exonuclease III from E. coli. , 1982, Nucleic acids research.

[43]  W. Haseltine,et al.  Use of exonuclease III to determine the site of stable lesions in defined sequences of DNA: the cyclobutane pyrimidine dimer and cis and trans dichlorodiammine platinum II examples. , 1981, Nucleic acids research.

[44]  K. Kohn,et al.  Thiourea reverses cross-links and restores biological activity in DNA treated with dichlorodiaminoplatinum (II). , 1979, Science.